- Previous Close
550.60 - Open
545.00 - Bid 547.35 x --
- Ask 547.85 x --
- Day's Range
534.80 - 549.10 - 52 Week Range
470.10 - 736.30 - Volume
93,776 - Avg. Volume
584,095 - Market Cap (intraday)
131.084B - Beta (5Y Monthly) --
- PE Ratio (TTM)
34.20 - EPS (TTM)
16.02 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
657.00
Indegene Limited operates as a life sciences commercialization company in India, the United States, Europe, and internationally. It operates through three segments: Enterprise Medical Solutions, Enterprise Commercial Solutions, and Omnichannel Activation & Others. The company develops biotech and medical device for biopharmaceutical, emerging biotech, and medical device companies. It also offers enterprise commercial, medical, and clinical solutions; and omnichannel activation solutions. In addition, the company operates NEXT technology platforms. Further, it provides analytics, technology, commercial, medical, regulatory, and safety services to life science and healthcare organizations. Indegene Limited was incorporated in 1998 and is based in Bengaluru, India.
www.indegene.com4,367
Full Time Employees
March 31
Fiscal Year Ends
Sector
Industry
Recent News: INDGN.NS
View MorePerformance Overview: INDGN.NS
Trailing total returns as of 4/9/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: INDGN.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: INDGN.NS
View MoreValuation Measures
Market Cap
131.74B
Enterprise Value
117.85B
Trailing P/E
34.32
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.78
Price/Book (mrq)
5.58
Enterprise Value/Revenue
4.28
Enterprise Value/EBITDA
18.63
Financial Highlights
Profitability and Income Statement
Profit Margin
13.93%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
27.57B
Net Income Avi to Common (ttm)
3.84B
Diluted EPS (ttm)
16.02
Balance Sheet and Cash Flow
Total Cash (mrq)
14.67B
Total Debt/Equity (mrq)
3.73%
Levered Free Cash Flow (ttm)
--